Table 1 Summary of basic characteristics of included trials evaluating dose-dense regimen vs. conventional three-week paclitaxel chemotherapy in epithelial ovarian cancer

JGOG3016 [13]

2013

Japan

II–IV

EOC

631(312: 319)

1: q3W P 180 mg/m² + q3W C AUC 6

2: q1W P 80 mg/m² + q3W C AUC6

28.2 m vs. 17.5 m

(HR = 0.76; p = 0.0037)

Median OS:

100.5 m vs. 62.2 m

(HR = 0.79; p = 0.039)

MITO-7 [11]

2014

Italy, France

IC–IV

810(409:404)

1: q3W P 175 mg/m² + q3W AUC 6

2: q1W P 60 mg/m² + q1W C AUC 2

17.3 m vs. 18.3 m

(HR = 0.96; p = 0.66)

2 years OS:

78.9% vs. 77.3%

(HR = 1.2; p = 0.22)

GOG 0262 [10]

2016

US, Canada, South Korea

II-IV

692(346:346)

1: q1W P 80 mg/m² + q3W C AUC6

2: q3W P 175 mg/m² + q3W C AUC 6

Not receive bevacizumab:

14.2 m vs. 10.3 m

(HR = 0.62; p = 0.03)

ICON8 [6]

2019

European

IC-IV

1566 (522:

522:522)

1: q3W P 175 mg/m² + q3W C AUC 5–6

2: q1W P 80 mg/m² + q3W C AUC 5–6

3: q1W P 80 mg/m² + q1W C AUC 2

17.7 m vs. 20.8 m vs. 21.0 m

(HR = 0·9 – arms 2 vs. 1)

(HR = 0.93 – arms 3 vs. 1)

Median OS^a:

HR = 0·90(0.74–1.1) – arms 2 vs 1

HR = 0.88(0.71–1.07) – arms 3 vs 1